Health Sciences

Penn Medicine’s Gary Lichtenstein, MD, a professor of Medicine and Gary Wu, MD, the Ferdinand G.

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the

Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient’s immune system – a weakness that in principle could be corrected with a HER2-targeted vaccine – according to a new study from the Perelman School of Medicine at the University of Pennsylvania. Results of the study show that T cells from patien

Anil K. Rustgi, MD, chief of Gastroenterology in the Perelman School of Medicine at the University of Pennsylvania, is once again the recipient of a prestigious Research Professor Award from the American Cancer Society (ACS).

For the third of all epilepsy patients who don’t respond to medication, an alternative is to locate the small cluster of neurons that act as the seed of a seizure’s aberrant electrical activity and surgically remove it. Unfortunately, such surgeries often fail to bring any relief.

We’ve all been there: Sitting in a consultation with a doctor or nurse, jargon gets thrown around, time with the health-care provider is short and, soon after the conversation concludes, you forget half of what you were told.

They are a natural pairing, two elements of every good bedtime routine: reading books and brushing teeth. But many young children, especially those in underserved communities, aren’t consistently doing either.

In rural Malawi, roughly 10 percent of the adult population has HIV.

Whether aspirin may help prevent or reduce the risk of breast cancer remains a hotly debated research question. While past studies have indicated a potential benefit, most recently in hormone receptor-positive breast cancers, one new study from Penn Medicine suggests otherwise.

Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor (ER) positive breast cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania.